Engineered small pox may kill liver cancer
As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma (HCC) or liver cancer. Pexa-Vec ...
Cancer
Apr 10, 2013 |
5 / 5 (2) |
0
Temple researchers show targeted cancer drug may stunt heart's ability to repair itself
Scientists for the first time have evidence showing how a widely used type of "targeted" cancer drug can be dangerous to the heart.
Cardiology
Nov 06, 2012 |
4 / 5 (2) |
0
|
Phase III data in treatment of renal cell carcinoma reported
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.
Cancer
Oct 01, 2012 |
not rated yet |
0
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer
Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO ...
Cancer
Sep 29, 2012 |
not rated yet |
0
Possible new therapy for the treatment of myeloma
(Medical Xpress)—Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common ...
Cancer
Sep 05, 2012 |
not rated yet |
0
|
Molecular imaging signals new treatment protocol for kidney cancer
Research revealed at the Society of Nuclear Medicine's 2012 Annual Meeting explores treatment with a newly developed type of radioimmunotherapy used for treating a resistant form of kidney cancer. The agent is able to hone ...
Cancer
Jun 11, 2012 |
not rated yet |
0
Scientists see potential in novel leukemia treatment
Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill ...
Cancer
May 22, 2012 |
5 / 5 (3) |
0
Combination of 2 drugs reverses liver tumors
The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research ...
Medications
May 02, 2012 |
not rated yet |
0
Three 'targeted' cancer drugs raise risk of fatal side effects
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects, according to a new analysis led by scientists at Dana-Farber Cancer Institute. They added that ...
Cancer
Feb 06, 2012 |
5 / 5 (1) |
0
|
Sorafenib effective in patients with non-small cell lung cancer, but low survival rates reported
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory," according to data presented at the AACR-IASLC Joint Conference on Molecular Origins ...
Cancer
Jan 10, 2012 |
not rated yet |
0
Panel of melanoma mutations opens door to new treatment possibilities
Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients with melanoma and the unique genetic mutations that may accompany the disease, according to data ...
Cancer
Nov 15, 2011 |
5 / 5 (1) |
0
'Micro'-chemo and cancer pill combo tested in liver cancer patients
A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these ...
Cancer
Sep 30, 2011 |
5 / 5 (3) |
0
|
Combining therapies appears safe, may benefit patients with advanced liver cancer
(Medical Xpress) -- Few treatments exist for patients with advanced primary liver cancer, but University of Florida researchers have found a new way to broaden the range of options and potentially improve health outcomes ...
Cancer
Jul 06, 2011 |
4 / 5 (1) |
0
|
Patients treated with sunitinib and sorafenib respond to flu vaccine
Patients treated with sunitinib and sorafenib responded to the flu vaccine, which suggests the agents do not damage the immune system as much as previously feared, according to a study in Clinical Cancer Research, a journa ...
Cancer
Jun 28, 2011 |
not rated yet |
0
Low-dose sorafenib may improve therapy for head and neck cancer
Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, according to a new study by researchers ...
Cancer
May 16, 2011 |
not rated yet |
0
|
- Pages: 1
